Effects of two new α-glucosidase inhibitors on glycemic control in patients with insulin-dependent diabetes mellitus
- 1 May 1986
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 64 (9) , 405-410
- https://doi.org/10.1007/bf01727525
Abstract
BAYo1248 and BAYm1099 are two new α-glucosidase inhibitors. Postprandial glucose tolerance was significantly improved and post-prandial insulin requirements were significantly reduced as compared to placebo after breakfast and lunch when 20 mg BAYo1248 were administered prior to breakfast and after breakfast, lunch and dinner when 50 mg BAYm1099 were given prior to all three main meals. Postprandial breath H2 concentrations were mildly increased when these α-glucosidase inhibitors were given and no patient complained of any adverse effects (such as flatulence, abdominal pain or diarrhea). BAYo1248 and BAYm1099 might be useful adjuncts to insulin in the treatment of patients with insulin-dependent diabetes mellitus.This publication has 12 references indexed in Scilit:
- α-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitusMetabolism, 1985
- A New Approach to the Treatment of Nocturnal Hypoglycemia Using Alpha-Glucosidase InhibitionDiabetes Care, 1983
- Importance of Timing of Preprandial Subcutaneous Insulin Administration in the Management of Diabetes MellitusDiabetes Care, 1983
- Lactose malabsorption in Greek adults: correlation of small bowel transit time with the severity of lactose intolerance.Gut, 1982
- Effects of the disaccharidase inhibitor acarbose on meal and intravenous glucose tolerance in normal manMetabolism, 1982
- Scope and Specificity of Acarbose in Slowing Carbohydrate Absorption in ManDiabetes, 1981
- Improvement of metabolic control in insulin dependent diabetics treated with the ?-glucosidase inhibitor Acarbose for two monthsDiabetologia, 1981
- Effect of the?? glucosidase-inhibitor BAY-g-5421 on blood glucose control of sulphonylurea-treated diabetics and insulin-treated diabeticsDiabetologia, 1979
- Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor.BMJ, 1979
- BREATH-HYDROGEN TEST AND SMOKINGThe Lancet, 1977